Входя на эту страницу, Вы подтверждаете, что являетесь  медицинским работником.

Status message

Not the entire site translated, but only to "Magazine"

Efficacy and safety of lurasidone in schizophrenia (literature review)

Oleneva E.V., Ryvkin P.V.
FGBU “National medical research centre of psychiatry and narcology by name of V.P. Serbsky” Minzdrava of Russian Federation, Moscow, Russia

Summary: The article discusses the most important features of a novel atypical antipsychotic agent lurasidone in terms of the recent treatment approach to schizophrenia patietns, such as its antirelapse and antidepressant activity, a favorable safety profile, as well as a procognitive effect. It includes core randomized placebo- and active comparator controlled clinical trials, which demonstrated a convincing efficacy of lurasidone for different symptom domains of schizophrenia compared to placebo and comparability with the efficacy of other atypical antipsychotics. A number of practical recommendations for use of lurasidone are given.

Contact: k_oleneva@mail.ru

References: 

1. Charlson F. et al. Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016 // Schizophrenia Bulletin. – 2018. – Vol. 44, Issue 6. – P. 1195–1203.
2. Kachaeva M.A., Shport S.V., Trushchelev S.A. Ctrategicheskie napravleniya deyatel'nosti VOZ po okhrane psikhicheskogo zdorov'ya naseleniya// Rossiiskii psikhiatricheskii zhurnal. – 2017. – № 6. – S. 10-23.
3. Brown S., Inskip H., Barraclough B. Causes of the excess mortality of schizophrenia // Br J Psychiatry. – 2000. – Vol. 177. – P. 212–217.
4. Bushe C.J., Tayljr M., Haukka J. Mortality in schizophrenia: a measurable clinical endpoint // J. Psychopharmacol. – 2010. – Vol. 24, No 11, Suppl. 4. – P. 17–25.
5. Standarty okazaniya pomoshchi bol'nym shizofreniei / pod red. V.N. Krasnova, I.Ya. Gurovicha, S.N. Mosolova, A.B. Shmuklera. – M: izdatel'skii tsentr «Akademiya», 2006. – 58 s.
6. Psikhiatriya. Natsional'noe rukovodstvo. Kratkoe izdanie / pod red. T.B. Dmitrievoi, V.N. Krasnova, N.G. Neznanova, V.Ya. Semke, A.S. Tiganova. – M.: GEOTAR-Media, 2012. – 624 s.
7. Mosolov S.N., Tsukarzi E.E. Psikhofarmakoterapiya shizofrenii // Psikhiatriya: natsional'noe rukovodstvo / pod red. N.G. Neznanova, Yu.A. Aleksandrovskogo. – M.: GOETAR-Media, 2018. – S. 299–328.
8. Bekker R.A., Bykov Yu.V..Effektivnost' i bezopasnost' antipsikhotika III pokoleniya lurazidona (Latuda) pri shizofrenii i bipolyarnykh depressiyakh (obzor literatury s kommentariyami) // Psikhiatriya i psikhofarmakoterapiya im. P.B. Gannushkina. – 2019. – № 4. – S. 20–33.
9. Sadock B., Sadock V., Ruiz P. Kaplan & Sadock’s comprehensive textbook of psychiatry. – 10th ed. – Philadelphia: Wolters Kluwer – 2017. – Vol. 2. – 4997 p.
10. Gershon S., Soares J. Bipolar disorders: basic mechanisms and therapeutic implications. – CRC Press, 2000. – 580 p.
11. Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. // World J Biol Psychiatry 2013, 14 (1):2-44.
12. Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. //World J Biol Psychiatry 2012;13 (5):318-
13. National Institute for Health and Care Excellence. Clinical Guideline 178. Psychosis and schizophrenia in adults: prevention and management. – 2014. –Available at: https://www.nice.org.uk/guidance/cg178/resources/psychosis-and-schizophr... (Accessed 24 Apr 2019).
14. Barnes T., Schizophrenia Consensus Group of British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology // J Psychopharmacol. – 2011. – Vol. 25. – P. 567–620.
15. Javed A. et al. Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia. // Neurol Ther. – 2019. – P. 1–16.
16. Mosolov S.N. Osnovy psikhofarmakoterapii. – M.: Vostok, 1996. – 242 s.
17. Leucht S., Leucht C., Huhn M. et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors // Am J Psychiatry. – 2017. – Vol.174, No. 10. – P. 927–942.
18. Huhn M. et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis // Lancet. – 2019. – Vol. 394, No. 10202. – P. 939–951. – Published Online July 11, 2019. – Available at: http://dx.doi.org/10.1016/ S0140-6736(19)31135-3.
19. Lieberman J., Stroup T., McEvoy J. et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia // N Engl J Med. – 2005. – Vol. 353. – P. 1209–1223.
20. Jones P., Barnes T., Davies L. et al. Randomized controlled trial of the effect on quality of life of second -–vs first-generation antipsychotic drugs in schizophrenia: cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) // Arch Gen Psychiatry. – 2006. – Vol. 63. – P. 1079–1087.
21. Miyamoto S., Miyake N., Jarskog L. et al. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents // Mol Psychiatry. – 2012. – Vol. 17. – P. 1206–1227.
22. Mosolov S.N., Tsukarzi E.E., Kapiletti S.G. Antipsikhoticheskaya farmakoterapiya shizofrenii: ot nauchnykh dannykh k klinicheskim rekomendatsiyam // Biologicheskie metody terapii psikhicheskikh rasstroistv. Dokazatel'naya meditsina – klinicheskoi praktike / pod red. S.N. Mosolova. – M.: Sotsial'no-politicheskaya mysl', 2012. – S. 11–61.
23. Krasnov V.N., Gurovich I.Ya., Mosolov S.N., Shmukler A.B., Tsukarzi E.E. Federal'nye klinicheskie rekomendatsii po diagnostike i lecheniyu shizofrenii. Elektronnyi resurs / Moskva, 2013. http://psychiatr.ru/download/1269?
24. Mosolov S.N., Ryvkin P.V., Serditov O.V., Ladyzhenskii M.Ya., Potapov A.V. Metabolicheskie pobochnye effekty sovremennoi antipsikhoticheskoi farmakoterapii // Sotsial'naya i klinicheskaya psikhiatriya. – 2008. – T. 18, № 3. – S. 75–90.
25. Federal'noe rukovodstvo po ispol'zovaniyu lekarstvennykh sredstv (formulyarnaya sistema) / pod red. A.G. Chuchalina, Yu.B. Belousova, V.V. Yasnetsova. − 8-e izd., pererab. i dop. − M.: Ekho, 2007 (M.: Shcherbinskaya tipografiya). − 1003 s.
26. Haddad P. Weight change with atypical antipsychotics in the treatment of schizophrenia // J Psychopharmacol. – 2005. – Vol.19, Suppl. 6. – P. 16–27.
27. Mosolov S.N., Kabanov S.O. Metabolicheskie narusheniya pri antipsikhoticheskoi terapii. // Sotsial'naya i klinicheskaya psikhiatriya. – 2003. – T. 13, № 2. – S. 162–172.
28. Kroeze W., Hufeisen S., Popadak B. et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. // Neuropsychopharmacology. – 2003. – Vol. 28, No 3. – P. 519–26.
29. Federal'noe rukovodstvo po ispol'zovaniyu lekarstvennykh sredstv (formulyarnaya sistema) / pod red. A.G. Chuchalina. − Vyp. IV. − M.: Ekho, 2003. − 956 s.
30. Neznanov N.G., Mosolov S.N., Ivanov M.V. Psikhofarmakoterapiya // Psikhiatriya: natsional'noe rukovodstvo / pod red. N.G. Neznanova, Yu.A. Aleksandrovskogo. − M.: GEOTAR-Media, 2018. − 976 s. − S. 820−893.
31. Karlson A., Lekrub'e I. Dofaminovaya teoriya patogeneza shizofrenii. Rukovodstvo dlya vrachei / Red. Mosolov S.N. – London, 2004.
32. Stahl S. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. – Cambridge: Cambridge University Press, 2013. – 656 p.
33. Cruz M. Lurasidone HCl (Latuda), an Oral, Once-Daily Atypical Antipsychotic Agent for the Treatment of Patients with Schizophreni // P T. – 2011. – No. 36 (8). – P. 489–492.
34. Owen R. Lurasidone: a new treatment option for schizophrenia // Drugs Today (Barc). – 2011. – Vol. 47, No. 11. – P. 807–816.
35. Nakamura M., Ogasa M., Guarino J. et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial // J Clin Psychiatry. – 2009. – Vol. 70. – P. 829–836.
36. Meltzer H., Cucchiaro J., Silva R. et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study // Am J Psychiatry. – 2011. – Vol. 168. – P. 957–967.
37. Ogasa M., Kimura T., Nakamura M., Guarino J. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study // Psychopharmacology (Berl.). – 2013. – Vol. 225. – P. 519–530.
38. Nasrallah H., Silva R., Phillips D. et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study // J Psychiatr Res. – 2013. – Vol. 47. – P. 670–677.
39. Loebel A., Cucchiaro J., Sarma K. et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial // Schizophr Res. – 2013. – Vol. 145. – P. 101–109.
40. Overall, J., Gorham, D. The brief psychiatric rating scale // Psychological Reports. – 1962. – No 10. – P. 790–812.
41. Loebel A., Silva R., Goldman R., et al. Lurasidone dose escalation in early nonresponding patients with schizophrenia: a randomized, placebo-controlled study // J Clin Psychiatry. – 2016. – Vol. 77. – P. 1672–1680.
42. Lindenmayer J.P., Grochovski S., Hyman R.B. Five factor model of schizophrenia: replication across samples // Schizophr Res. – 1995. – Vol. 14. – P. 229–234.
43. Marder S.R., Davis J.M., Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials // J Clin Psychiatry. – 1997. – Vol. 58. – P. 538–546.
44. Mosolov S.N., Kuzavkova M.V., Kalinin V.V., Eremin A.V., Sulimov G.Yu. Analiz vliyaniya atipichnykh antipsikhotikov na 5-faktornuyu model' shizofrenii // Sotsial'naya i klinicheskaya psikhiatriya. – 2003. – T. 13, № 3. – S. 45–52.
45. Lindenmayer J.P., Czobor P., Volavka J., Lieberman J.A., Citrome L., Sheitman B. et al. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia // J Clin Psychiatry. – 2004. – Vol. 65. – P. 551–556.
46. Loebel A., Cucchiaro J., Silva R., Mao Y., Xu J., Pikalov A., Marder S.R. Efficacy of lurasidone across five symptom dimensions of schizophrenia: Pooled analysis of short-term, placebo-controlled studies // European Psychiatry. – 2015. – Vol. 30. – P. 26–31.
47. Nasrallah A., Cucchiaro J., Mao Y. et al. Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies // CNS Spectrums. – 2015. – No. 20. – P. 140–147.
48. Emsley R., Chiliza B., Asmal L. The evidence for illness progression after relapse in schizophrenia // Schizophr.Res. – 2013. – Vol. 148. – P. 117–121.
49. Kane J. Treatment strategies to prevent relapse and encourage remission // J Clin Psychiatry. – 2007. – Vol. 68. – P. 27–30.
50. Tandon R., Nasrallah H., Keshavan M. Schizophrenia, “just the facts” 4. Clinical features and conceptualization // Schizophr.Res. – 2009. – Vol. 110. – P. 1–23.
51. Mosolov S., Potapov A.V., Ushakov U.V., Shafarenko A.A., Kostyukova A.B. Design and validation of standardized clinical and functional remission criteria in schizophrenia // Neuropsychiatric Disease and Treatment. 2014, Vol.10, p.167-181.
52. Mosolov S.N., Potapov A.V., Tsukarzi E.E. Standartizirovannye kliniko-funktsional'nye kriterii terapevticheskoi remissii pri shizofrenii: metodich. ukazaniya. – M.: FGBU «NMITsPN im. V.P. Serbskogo» MZ RF, 2017. – 73 s.
53. Goff D., Hill M., Freudenreich O. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder // J Clin Psychiatry. – 2010. – Vol. 71, Suppl. 2. – P. 20–26.
54. Glick I., Correll C., Altamura A., Marder S., Csernansky J., Weiden P., et al. Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach // J Clin Psychiatry. – 2011. – Vol. 72. – P. 1616–1627.
55. Mosolov S.N. Protivoretsidivnaya terapiya bol'nykh shizofreniei. pochemu vazhno nachinat' ee na rannikh etapakh zabolevaniya? // Psikhicheskoe zdorov'e cheloveka i obshchestva. Aktual'nye mezhdistsiplinarnye problemy: nauch.-prakt. konf.: sb. mater. / pod red. G.P. Kostyuka. – M., 2018. – S. 286–306.
56. Tandon R. et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia // Journal of Psychopharmacology. – 2016. – Vol. 30 (1). – P. 69–77.
57. Loebel A. at al. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind, noninferiority study // Schizophrenia Research. – 2013. – Vol. 147. – P. 95–102.
58. Andreasen N., Carpenter Jr., Kane J. et al. Remission in schizophrenia: proposed criteria and rationale for consensus // Am J Psychiatry. – 2005. – Vol. 162. – P. 441–449.
59. Citrome L. et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study // International Clinical Psychopharmacology. – 2012. – Vol. 27, Issue 3. – P. 165–176.
60. Pietrzak R., Olver J., Norman T. et al. A comparison of the CogState schizophrenia battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia // J Clin Exp Neuropsychol. – 2009. – Vol. 31. – P. 848–859.
61. Mausbach B., Harvey P., Goldman S. et al. Development of a brief scale of everyday functioning in persons with serious mental illness // Schizophr. Bull. – 2007. – Vol. 33. – P. 1364–1372.
62. Harvey P., Siu C., Hsu J. et al. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension // Eur Neuropsychopharmacol. – 2013. – Vol.23. – P. 1373–1382.
63. Harvey P., Ogasa M., Cucchiaro J. et al. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone // Schizophr Res. – 2011. – Vol. 127. – P.188–194.
64. Harvey P., Siu C., Ogasa M., Loebel A. Effect of lurasidone dose on cognition in patients with schizophrenia: Post-hoc analysis of a long-term, double-blind continuation study // Schizophr Res. – 2015. – Vol. 166 (1–3). – P. 334–338.
65. de Boer M., Castelein S., Wiersma D. et al. The facts about sexual (Dys)function in schizophrenia: an overview of clinically relevant findings // Schizophr Bull. – 2015. – Vol. 41. – P. 674–686.
66. Newcomer J. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence // J Clin Psychiatry. – 2007. – Vol. 68, Suppl. 1. – P. 20–27.
67. Dayabandara M., Hanwella R., Ratnatunga S., et al. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence // Neuropsychiatr Dis Treat. – 2017. – Vol. 13. – P. 2231–2241.
68. Citrome L. Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harm // J Clin Psychopharmacol. – 2017. – Vol. 37. – P. 138–147.
69. Sunovion Pharmaceuticals Europe Ltd. Latuda. Summary of product characteristics. – 2019. -https://www.medicines.org.uk/emc/medicine/29125. Accessed 24 Apr 2019.
70. Preskorn S., Ereshefsky L., Chiu Y., et al. Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies. // Hum. Psychopharmacol. – 2013. – Vol.28. – P.495–505.
71. Solmi M., Murru A., Pacchiarotti I., et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. // Ther. Clin. Risk Manag. – 2017. – Vol.13. – P.757–777.
72. Lehman A., Lieberman J., Dixon L. et al. American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, 2nd edn. // Am J Psychiatry. – 2004. – Vol. 161, Suppl. 2. – P. 1–56.
73. Holloman L., Marder S. Management of acute extrapyramidal effects induced by antipsychotic drugs // Am J Health Syst. Pharm. – 1997. – Vol. 54. – P. 2461–2477.
74. Cooper S., Reynolds G. et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment // J Psychopharmacol. – 2016. – Vol. 30. – P. 717–748.
75. Taylor D., Barnes T., Young A. The Maudsley prescribing guidelines in psychiatry. – 13th edn. – Oxford: Wiley Blackwell, 2018. – 1455 c.
76. Psikhiatriya: natsional'noe rukovodstvo / pod red. N.G. Neznanova, Yu.A. Aleksandrovskogo. – M.: GOETAR-Media, 2018.